In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

Lateral flow assay applications have become increasingly diverse in a post-pandemic world, and the areas of infectious disease and oncology continue to be at the forefront. In both areas, the use of ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

The COVID-19 pandemic and geopolitical conflict in Eastern Europe have done irreparable damage to the underpinnings of the clinical diagnostic industry. These events significantly impacted the supply ...

This article and associated images are based on a poster originally authored by Linda Kitching, Maxime Couturier, Jonathan Tart, Erik Elebring, Marcel Taillefer, Claudio Pathe, Giulia Bonetto, ...

As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...

A new Armatus publication summarizes a novel potency assay platform to advance gene silencing therapies for rare neuromuscular diseases.

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...